Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.00218-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Yoshifumi Uwamino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Azithromycin, Microbial Sensitivity Tests, Mycobacterium avium Complex, Clarithromycin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyokuto Pharmaceuticals, Inc., Oyama Health Foundation, MEXT | Japan Science and Technology Agency (JST).
Abstract (Originalsprache)
The latest guidelines include azithromycin as a preferred regimen for treating Mycobacterium avium complex (MAC) pulmonary disease. However, serially collected susceptibility data on clinical MAC isolates are limited, and no breakpoints have been determined. We investigated the minimum inhibitory concentrations (MICs) of azithromycin and clarithromycin for all MAC strains isolated in 2021 from a single center in Japan, excluding duplicates. The MICs were determined using a panel based on the microbroth dilution method, according to the latest Clinical and Laboratory Standards Institute recommendations. The MICs were determined for 318 MAC strains. Although there was a significant positive correlation between the MICs of azithromycin and clarithromycin, the MICs of azithromycin tended to be higher than those of clarithromycin. Among the cases in which the strains were isolated, 18 patients initiated treatment, including azithromycin treatment, after sample collection. Some patients infected with stains with relatively high azithromycin MICs achieved a microbiological cure with azithromycin-containing regimens. This study revealed a higher MIC distribution for azithromycin than clarithromycin, raising questions about the current practice of estimating azithromycin susceptibility based on the clarithromycin susceptibility test result. However, this was a single-center study that included only a limited number of cases treated with azithromycin. Therefore, further multicenter studies that include a greater number of cases treated with azithromycin are warranted to verify the distribution of azithromycin MICs and examine the correlation between azithromycin MICs and treatment effectiveness. IMPORTANCE The macrolides serve as key drugs in the treatment of pulmonary Mycobacterium avium complex infection, and the administration of macrolide should be guided by susceptibility test results. Azithromycin is recommended as a preferred choice among macrolides, surpassing clarithromycin; however, drug susceptibility testing is often not conducted, and clarithromycin susceptibility is used as a surrogate. This study represents the first investigation into the minimum inhibitory concentration of azithromycin on a scale of several hundred clinical isolates, revealing an overall tendency for higher minimum inhibitory concentrations compared with clarithromycin. The results raise questions about the appropriateness of using clarithromycin susceptibility test outcomes for determining the administration of azithromycin. This study highlights the need for future discussions on the clinical breakpoints of azithromycin, based on large-scale clinical research correlating azithromycin susceptibility with treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
- Clinical Laboratory, Keio University Hospital, Tokyo, Japan.
- Keio University Health Center, Tokyo, Japan.
ORCID-Profile: Yoshifumi Uwamino, Naoki Hasegawa
Förderung
- Kyokuto Pharmaceuticals, Inc.
- Oyama Health Foundation
- MEXT | Japan Science and Technology Agency (JST)
Zitieren
APA
Uwamino, Y., Aoki, W., Inose, R., Kamoshita, Y., Mikita, K., Namkoong, H., Nishimura, T., Matsushita, H., & Hasegawa, N. (2024). Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00218-24
Vancouver
Uwamino Y, Aoki W, Inose R, Kamoshita Y, Mikita K, Namkoong H, et al. Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00218-24
BibTeX
@article{Uwamino2024,
author = {Uwamino, Yoshifumi and Aoki, Wataru and Inose, Rika and Kamoshita, Yuka and Mikita, Kei and Namkoong, Ho and Nishimura, Tomoyasu and Matsushita, Hiromichi and Hasegawa, Naoki},
title = {Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.00218-24}
}
EUVIMED